Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
November 24, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.
November 18, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
November 17, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in...
October 20, 2025 07:00 ET | Source: BPGbio

BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease

New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain and creates new frontier for drug research
October 16, 2025 05:01 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

The company aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk, often before clinical symptoms appear.
October 01, 2025 06:01 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

RetinalGenix Technologies and RGEN Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.
September 25, 2025 06:15 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care

RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
May 13, 2025 17:00 ET | Source: Claritas HealthTech Ltd

Claritas Neurocloud™ for Brain Imaging Analysis to Commence Commercialization on Execution of Partnership between Claritas and Qubiotech

LONDON and SAO PAULO, May 13, 2025 (GLOBE NEWSWIRE) -- Claritas HealthTech Limited (“Claritas”), a healthcare technology company specializing in advanced medical image processing, segmentation, and...
May 05, 2025 06:15 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs

APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life...